Abstract
DNA vaccination is currently being explored as a potential strategy for combatting cancer. However, tumor antigens are often weak and the immune system of patients may be compromised. For B-cell tumors, immunoglobulin idiotypic antigens provide defined targets but are poorly immunogenic. Fusion of a sequence derived from tetanus toxin to the genes encoding idiotypic determinants has proved highly effective in activating protective anti-tumor immunity. DNA fusion vaccines containing immuno-enhancing sequences can augment and direct immune attack on a range of target antigens. Gene-based fusion vaccines offer ease of manipulation and flexible design to activate effective attack on cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, Neoplasm / immunology
-
Cancer Vaccines / genetics*
-
Cancer Vaccines / immunology*
-
Cancer Vaccines / therapeutic use
-
Humans
-
Immunoglobulin Idiotypes / immunology
-
Immunotherapy / methods
-
Lymphoma, B-Cell / genetics*
-
Lymphoma, B-Cell / immunology*
-
Lymphoma, B-Cell / therapy
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology*
-
Tetanus Toxin / genetics
-
Tetanus Toxin / metabolism
-
Vaccines, DNA / genetics*
-
Vaccines, DNA / immunology
-
Vaccines, DNA / therapeutic use*
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
Immunoglobulin Idiotypes
-
Recombinant Fusion Proteins
-
Tetanus Toxin
-
Vaccines, DNA